Buy or sell Cartiva stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Cartiva Stock

Cartiva is a developer of innovative products for the treatment of cartilage injuries and osteoarthritis.

Founded

2011

Notable Investors

Headquarters

Alpharetta GA, US

Total Funding

$24.3M

About Cartiva Stock

Cartiva, Inc., located in Alpharetta, Georgia, is a private, venture capital-backed company that was spun out from Carticept Medical, Inc. in December 2011. Cartiva is dedicated to improving the quality of life for patients with osteoarthritis or cartilage damage through the development of novel therapies. An estimated 27 million Americans suffer from osteoarthritis, a chronic degenerative joint disease characterized by the breakdown of the cartilage in the joint. An additional two million Americans injure the cartilage in their knees each year. Many people do not respond well to current medical treatments or are not eligible for major surgery such as a total joint replacement. Cartiva’s mission is to develop and market products to help physicians treat osteoarthritis and cartilage injuries and the related pain more effectively. Our management team, board of directors and medical advisors are comprised of industry-recognized professionals who possess broad knowledge in orthopedics and extensive experience managing innovative medical devices from development through clinical trials, FDA approval and successful commercialization.

Funding History

July 2013$4.3M
January 2014$1.5M
December 2014$1.5M
May 2015$8.5M
January 2017$8.5M

Management

Director, Clinical Affairs

Katie E. Strother

VP, Regulatory, Quality & Clinical Affairs

Deborah J. Moore

President, CEO & Board of Directors

Timothy J. Patrick

VP, Finance & CFO

Peter J. Pizzo

Other Companies

Logo
Emulate

Emulate, Inc. is a private company focused on commercializing Organs-on-Chips.

Logo
Higi

Higi's platform enables & empowers users to self-screen their biometrics & share that data with a trusted health professional.

Logo
Recursion Pharmaceuticals

Artificial intelligence to discover treatments

Logo
Rubius Therapeutics

Rubius is developing a new class of drugs, Red-Cell Therapeutics™,

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Cartiva or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 70K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo

Logo